Kyverna Therapeutics
Clinical trials sponsored by Kyverna Therapeutics, explained in plain language.
Cell therapy company focused on autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- CAR t therapy takes on myasthenia gravis in major new trial Results expected Sep 2027 (estimated) May already have reported ↗ 🚀 Make-or-break
-
Experimental CAR-T therapy takes aim at Hard-to-Treat scleroderma
Disease control Stopped earlyThis early-phase trial is testing a new treatment called KYV-101 for people with systemic sclerosis, a disease where the immune system attacks the body, causing skin and organ damage. The therapy uses a patient's own modified immune cells to target and destroy certain B cells tha…
Phase 1/2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Could CAR-T cells tame tough lupus kidney disease?
Disease control Stopped earlyThis early-phase trial is testing a new treatment called KYV-101, which uses a patient's own modified immune cells (CAR-T cells) to target and destroy faulty B cells that drive lupus kidney inflammation. The study involves 6 adults with lupus nephritis that hasn't responded to st…
Phase 1/2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Experimental CAR-T therapy takes on Hard-to-Treat lupus nephritis
Disease control Stopped earlyThis early-phase trial is testing a personalized cell therapy called KYV-101 for people with lupus nephritis that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. Only 2 p…
Phase 1/2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC